Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 16/20 | 0.56 |
| ▸ | MMP13 | P45452 | 10/20 | 0.51 |
| ▸ | MMP1 | P03956 | 6/20 | 0.50 |
| ▸ | MMP9 | P14780 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7437127 | 0.92 | ADAM17 (0.67) | ADAM17MMP13MMP1MMP9KDM4E | |
| SCHEMBL7427544 | 0.87 | ADAM17 (0.60) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7421888 | 0.84 | ADAM17 (0.58) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7423131 | 0.84 | ADAM17 (0.53) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7428773 | 0.84 | ADAM17 (0.64) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6269908 | 0.79 | ADAM17 (0.84) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6268284 | 0.78 | ADAM17 (0.72) | ADAM17MMP13MMP1MMP9KDM4E | |
| SCHEMBL6263503 | 0.78 | ADAM17 (0.67) | ADAM17MMP13MMP1MMP9ALDH1A1 | |
| SCHEMBL7423765 | 0.77 | ADAM17 (0.67) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL4033569 | 0.72 | ADAM17 (0.82) | ADAM17MMP13MMP1MMP9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | WYETH | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | MMP17, MMP1, MMP9 | ADAM17 12/4885MMP13 16/4885MMP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.